Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04780984 · ClinicalTrials.gov registry record · Phase 2
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Nephron Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT04780984 is a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Nephron Pharmaceuticals Corporation. The registered enrollment target is 116 participants, below the 648-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04780984, a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Nephron Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2, Randomized, Partially-blinded, Parallel Group, Dose-ranging Study to Assess the Pharmacodynamics, Relative Bioavailability, and Safety of Three Doses of Tiotropium Bromide Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tiotropium bromide inhalation solution
Study Locations (1)
South Carolina
- Clinical Research of Rock Hill - Rock Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2021-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04780984
The ClinicalTrials.gov registry entry for NCT04780984 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 648-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (82% lower). The listed sponsor is Nephron Pharmaceuticals Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04780984 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT04780984 about?
NCT04780984 is a clinical study titled "Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease". A Phase 2, Randomized, Partially-blinded, Parallel Group, Dose-ranging Study to Assess the Pharmacodynamics, Relative Bioavailability, and Safety of Three Doses of Tiotropium Bromide Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease
What is the current status of trial NCT04780984?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2020-11-01. Estimated completion is 2021-04-26.
What conditions does trial NCT04780984 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT04780984?
The interventions under investigation include: Placebo (DRUG), Tiotropium bromide inhalation solution (DRUG).
Who is sponsoring clinical trial NCT04780984?
This trial is sponsored by Nephron Pharmaceuticals Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04780984 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 2
-
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)
COMPLETED · Phase 2
-
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
COMPLETED · Phase 2
-
Sodium Pyruvate Therapy in COPD Patients
COMPLETED · Phase 2
-
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.